Insulin Resistance in Children: Consensus, Perspective, and Future Directions


J. Clin. Endocrinol. Metab. 2010 95:5189-5198 originally published online Sep 8, 2010; doi: 10.1210/jc.2010-1047

To subscribe to Journal of Clinical Endocrinology & Metabolism or any of the other journals published by The Endocrine Society please go to: http://jcem.endojournals.org/subscriptions/
Insulin Resistance in Children: Consensus, Perspective, and Future Directions


Institut National de la Santé et de la Recherche Médicale, Unité 690 (C.L.-M., C.D.), Hôpital Robert Debré, 75019 Paris, France; Université Paris Diderot (C.L.-M., C.D.), 75013 Paris, France; Children’s Hospital of Pittsburgh (S.A.), University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15224; Liggins Institute (W.C.), University of Auckland, Auckland 1142, New Zealand; Department of Pediatrics (A.S.), University of Minnesota, Minneapolis, Minnesota 55455; and Department of Pediatrics (M.L.M., F.C.), University of Chieti, Chieti 66013, Italy

Objective: Emerging data indicate that insulin resistance is common among children and adolescents and is related to cardiometabolic risk, therefore requiring consideration early in life. However, there is still confusion on how to define insulin resistance, how to measure it, what its risk factors are, and whether there are effective strategies to prevent and treat it. A consensus conference was organized in order to clarify these points.

Participants: The consensus was internationally supported by all the major scientific societies in pediatric endocrinology and 37 participants.

Evidence: An independent and systematic search of the literature was conducted to identify key articles relating to insulin resistance in children.

Consensus Process: The conference was divided into five themes and working groups: background and definition; methods of measurement and screening; risk factors and consequences; prevention; and treatment. Each group selected key issues, searched the literature, and developed a draft document. During a 3-d meeting, these papers were debated and finalized by each group before presenting them to the full forum for further discussion and agreement.

Conclusions: Given the current childhood obesity epidemic, insulin resistance in children is an important issue confronting health care professionals. There are no clear criteria to define insulin resistance in children, and surrogate markers such as fasting insulin are poor measures of insulin sensitivity. Based on current screening criteria and methodology, there is no justification for screening children for insulin resistance. Lifestyle interventions including diet and exercise can improve insulin sensitivity, whereas drugs should be implemented only in selected cases. (J Clin Endocrinol Metab 95: 5189–5198, 2010)

Insulin resistance in adults has been recognized for decades as a cardinal feature in the development of type 2 diabetes (T2D) and has been associated with obesity, the metabolic syndrome, hypertension, and heart disease (1). It is also clear that insulin resistance is significantly related to obesity and cardiometabolic risk in children (2). However, there is a lack of clarity as to how insulin resistance in childhood is best assessed, in what clinical disorders it occurs, and whether it can be treated or prevented.

Abbreviations: DM, Diabetes mellitus; FSIVGTT, frequently sampled iv glucose tolerance test; GDM, gestational DM; HOMA, homeostasis model assessment; IGT, impaired glucose tolerance; LOE, level of evidence; NAFLD, nonalcoholic fatty liver disease; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; SSPP, steady-state plasma glucose; T2D, type 2 diabetes.
To address the current state of the art related to insulin resistance in children, the European Society for Pediatric Endocrinology (ESPE), the Lawson Wilkins Pediatric Endocrine Society (LWPES), the International Society for Pediatric and Adolescent Diabetes (ISPAD), the Asia Pacific Pediatric Endocrine Society (APPES), the Australasia Pediatric Endocrine Society (APEG), the Sociedad Latino-Americana de Endocrinologia Pediatrica (SLEP), and the Japanese Society for Pediatric Endocrinology (JSPE) convened a panel of experts for a consensus conference on childhood insulin resistance.

**Methods**

The conference used an evidence-based approach. An independent and systematic search of the literature was conducted through EMBASE and PubMed based on MeSH terms. Grading of the evidence was based on previously published American Diabetes Association standards (3). See Supplemental Data, published on The Endocrine Society’s Journals Online web site at http://jcem.endojournals.org.

**Definition and Background**

1. **Insulin resistance refers to reduced whole body glucose uptake [level of evidence (LOE) A; mostly in adults]**

   Insulin resistance is defined as the decreased tissue response to insulin-mediated cellular actions and is the inverse of insulin sensitivity. The term “insulin resistance,” as generally applied, refers to whole-body reduced glucose uptake in response to physiological insulin levels and its consequent effects on glucose and insulin metabolism. Euglycemic hyperinsulinemic clamp studies have shown that insulin resistance is determined primarily by the response of skeletal muscle, with over 75% of infused glucose taken up by muscle and only 2–3% by adipose tissue (4).

2. **Insulin resistance is a continuum (LOE A in adults)**

   Insulin sensitivity is a continuum from very low levels in individuals with high insulin resistance to very high levels in individuals without insulin resistance.

3. **Insulin resistance is commonly associated with obesity (LOE A in adults and children)**

   Insulin resistance is most commonly associated with obesity, although not all obese people are insulin resistant and insulin resistance may occur in nonobese children and adults (5–7). Insulin resistance can also occur during normal physiological conditions, such as pregnancy or puberty (8).

4. **One of the consequences of insulin resistance is chronic compensatory hyperinsulinemia (LOE A in adults, B in children)**

   Although the primary interest has been in insulin resistance, the adverse effects related to insulin resistance are more likely mediated via compensatory hyperinsulinemia (9). Despite the hyperinsulinemic response to insulin resistance, the current LOE does not support development of a definition of insulin resistance based on fasting insulin.

5. **Standards for insulin resistance in children, with definitions for normal and abnormal levels, are nonexistent (LOE C in children)**

   Standards for insulin resistance in children have not been established. This is due, in part, to the use of a variety of techniques to measure insulin sensitivity, lack of sufficient cohort sizes to establish normative distributions for insulin sensitivity, and lack of adequate longitudinal studies to relate definitions for insulin resistance to long-term outcomes. Clinical features, such as acanthosis nigricans, can point to the likelihood of insulin resistance but cannot define it. Fasting insulin is not an optimal tool for individual assessment of peripheral insulin sensitivity, but it may provide information regarding compensatory hyperinsulinemia and liver insulin metabolism. Depending on the study population, fasting insulin is not always well correlated with insulin resistance in children (10), and differences exist between the heritability of fasting insulin and insulin resistance (11). Many studies have used fasting insulin alone or in combination with fasting glucose as surrogates for insulin resistance, but these are poor substitutes for the direct measures, thus limiting their precision. Fasting insulin as an index of insulin resistance may be applicable in epidemiological studies using large populations of children and/or well-defined cohorts.

**Methods of Measurement**

6. **The euglycemic hyperinsulinemic clamp is the “gold standard” for measuring insulin sensitivity; the frequently sampled iv glucose tolerance test (FSIVGTT) and steady-state plasma glucose (SSPG) methods are also valid measurements (LOE A in adults, C in children)**

   The hyperinsulinemic euglycemic clamp, the FSIVGTT with modeling, and the SSPG are generally accepted as valid and reliable for measurement of insulin sensitivity. However, each of these methods is time consuming, requires iv infusions and frequent blood sampling, is bur-
denosome for participants, is costly, and requires a research setting.

Less intensive methods, such as measurement of insulin during the oral glucose tolerance test (OGTT), offer the advantage of a smaller number of blood samples. High correlations were reported in adult studies comparing the OGTT with the euglycemic hyperinsulinemic clamp (12). The OGTT has not been studied as well in children. In a group of 38 obese 8–18 yr olds, the correlation between the OGTT (whole-body insulin sensitivity index) and the euglycemic hyperinsulinemic clamp was 0.78 (13).

7. The homeostasis model assessment (HOMA) and the quantitative insulin-sensitivity check index do not offer any advantages over fasting insulin in euglycemic children (LOE A in adults, B in children)

In an attempt to further simplify the measurement of insulin sensitivity, a number of methods using single simultaneously obtained samples of fasting insulin and glucose have been developed. Each of these uses a mathematical formula that adjusts for individual variability in insulin and glucose secretion and clearance. Although the goal for these methods was to improve the accuracy of fasting insulin alone by the addition of fasting glucose, it is now agreed that they yield similar results to fasting insulin. For instance, HOMA, the most widely used of the surrogate measures in children, is highly correlated with fasting insulin \( r = 0.95 \) in children (10) and adults. These high correlations can be attributed to the narrow range of fasting glucose even among obese children and those with abnormal glucose tolerance (14, 15), whereas there is a 53-fold variation in fasting insulin in children (10).

8. Fasting insulin is a poor measure of whole body insulin sensitivity in an individual child (LOE A)

The accuracy of fasting insulin as a measure of insulin sensitivity has been assessed through correlation analyses with the euglycemic hyperinsulinemic clamp, FSIVGTT, or SSPG and found to be disappointingly low (16). Studies of cohorts (with more than 50 participants for this consensus statement) containing both grade school-aged and high school-aged children have reported correlations from 0.42–0.91 between fasting insulin and the clamp (10, 17) and from 0.18–0.8 between fasting insulin and FSIVGTT (18–21). In the largest cohort reported to date, the correlation between fasting insulin and the clamp was 0.42 at mean age of 13 yr (n = 323) and 0.29 at mean age of 15 yr (n = 300), with slightly higher correlations in obese than thin children (10). It can be concluded from these studies that fasting insulin is a poor measure of whole body insulin sensitivity in an individual child, and it should not be used for clinical decision making in daily clinical practice.

Although fasting insulin is a poor surrogate, much of the data relating to prevalence, intervention, and prevention are based on it or other surrogates, bringing into question the precision of the results from those studies.

Methods of Screening

9. Based on current screening criteria and methodology, there is no justification for screening children for insulin resistance, including obese children (LOE A)

The prevalence of insulin resistance is unknown, but it is clear that insulin-resistant obese children have significantly greater cardiovascular risk profiles, and childhood insulin resistance appears to predict future cardiovascular risk (21). Although this suggests that screening has the potential to identify at-risk children, the key issue for any screening program is availability of an accurate, reliable, reproducible, and easily applicable method of measurement. It is impractical to use any lengthy methods requiring multiple samples because of the complexity, time, and cost of individual testing. In the clinical setting, fasting insulin is an unreliable measure of insulin sensitivity, and testing of aliquots of a common sample assayed in different laboratories has shown disparate results (22). Even if a uniformly reliable insulin assay became available, separate standards would need to be developed by genders, ethnic groups, and pubertal stages (8, 23, 24). Currently, there is no recommended pharmacological treatment for isolated insulin resistance. Therefore, screening for insulin resistance is not justified in the clinical setting for children, including those with obesity. The mere presence of obesity should call for intervention to lower weight and consequently improve insulin sensitivity without a need to measure insulin levels.

Assessment of Risk Factors of Childhood Insulin Resistance

10. The two most important biological conditions associated with insulin resistance in childhood are ethnicity and puberty (LOE A)

Using a variety of methods, studies show that African-American, Hispanic, Pima Indian, and Asian children are less insulin sensitive compared with Caucasian children (25–27). The insulin resistance in minority ethnic groups is manifested as lower insulin-stimulated glucose uptake, concomitant with hyperinsulinemia, evidence of increased insulin secretion from the β-cell and decreased insulin clearance (25–27).

During puberty there is ~25–50% decline in insulin sensitivity with recovery when pubertal development is...
complete (8). The compensatory increase in insulin secretion during puberty may be blunted in African-American and Hispanic youth, thus increasing their risk for T2D around the time of puberty (28, 29).

11. Obesity, particularly increased abdominal visceral adiposity, and nonalcoholic fatty liver disease (NAFLD) are associated with insulin resistance in children (LOE A)

Obesity is the most prevalent pathophysiological cause of insulin resistance. Insulin sensitivity is inversely associated with body mass index and percentage body fat, and obese youth have lower insulin sensitivity than their normal-weight peers (30, 31). Independent of the relation between total body fat and insulin resistance, increased abdominal visceral adipose tissue in obese youth is associated with lower insulin sensitivity and higher acute insulin response (23). Limited studies show that ectopic fat deposition such as intramyocellular lipid in obese adolescents is also associated with decreased peripheral insulin sensitivity (32).

Studies using the clamp methodology demonstrate that NAFLD is associated with hepatic and peripheral insulin resistance (33). The relation between insulin sensitivity and NAFLD seems to be, in part, driven by abdominal fat content (34).

The relationship between lifestyle factors, e.g. nutrition and physical activity, and insulin sensitivity is poorly defined in children.

Increased caloric intake leading to obesity, rather than the dietary macronutrient composition, is associated with insulin resistance and hyperinsulinemia. Limited cross-sectional data suggest that dietary saturated fat and sugar-sweetened beverages may be associated with alterations in insulin sensitivity and secretion (35).

The effect of physical activity on insulin sensitivity, independent of changes in weight and adiposity, remains controversial.

12. Polycystic ovary syndrome (PCOS), independent of weight, is characterized by insulin resistance in childhood (LOE B)

Adolescent girls with PCOS can have severe insulin resistance with increased risk for impaired glucose tolerance (IGT) and T2D, and the impairment in insulin sensitivity is more pronounced in obese than lean PCOS girls (36, 37). In some ethnic groups, girls with premature pubarche, a potential antecedent of PCOS, have increased insulin levels, and a causal relation between hyperinsulinemia and adrenal and/or ovarian androgen hypersecretion has been hypothesized (38, 39). However, population studies of normal girls have shown that rapid weight gain is associated with higher adrenal androgens and body fatness, and that insulinemia was related to early menarche (40). Thus, the association of higher insulin levels with premature pubarche and subsequent PCOS may be driven, at least in part, by obesity.

13. Genetics and heritability play a role in childhood insulin resistance (LOE B)

In studies of adult twins, approximately half of the variance in insulin sensitivity and secretion can be attributed to genetic factors (41, 42). Healthy children with a family history of T2D are more insulin resistant, with an impaired balance between insulin sensitivity and secretion (43, 44). Recently, common genetic variants have emerged that identify heritable components of insulin sensitivity (45). The T2D protective variant Pro12Ala in PPAR-γ is associated with higher insulin sensitivity in Caucasian children (46).

14. Intrauterine exposure to poorly controlled maternal diabetes increases the risk of obesity, insulin resistance, and IGT in childhood (LOE B)

Epidemiological and clinical studies have demonstrated that offspring of mothers with preexisting diabetes mellitus (DM) or gestational DM (GDM) have an increased risk of obesity and altered glucose metabolism (47). Small size at birth or being large for gestational age is independently associated with increased risk of childhood obesity (and possibly altered glucose metabolism) (48), but the risk of obesity and IGT/diabetes is also higher in normal-weight offspring of mothers with DM or GDM (49). Infants of mothers with GDM have more body fat than infants born to mothers with normal glucose tolerance (50), but less is known about whether excess adiposity in these infants is a risk factor for obesity or insulin resistance in later life.

Higher levels of maternal glucose during pregnancy, with or without meeting criteria for the diagnosis of GDM, might play a role in the future risk of childhood obesity and insulin resistance in the offspring (51).
studies relating it to early infancy (0–6 months) and others between ages 2 and 11 yr (54–56).

The association between small-for-gestational-age infants and an increased risk of obesity, insulin resistance, and T2D is accentuated by weight gain during early life with increased percentage body fat (52, 59, 60).

Preterm children have reduced insulin sensitivity, which persists in adulthood and is associated with truncal obesity (61).

Consequences of Childhood Insulin Resistance

16. Insulin resistance is a risk factor for prediabetes and T2D in childhood (LOE B)

Insulin resistance and impaired β-cell function are the two key components in the pathogenesis of T2D in youth (62). Despite limited and conflicting cross-sectional data, it is well accepted that youth with IGT have impairment in insulin secretion compared with equally obese youths with normal glucose tolerance (63–65). In some studies, this has been associated with similar levels of insulin sensitivity (63, 65), whereas in others obese adolescents with IGT were more insulin resistant than adolescents with normal glucose tolerance and a similar degree of adiposity (32, 66). However, there are very limited longitudinal data on whether insulin resistance predicts the development of IGT and T2D. A recent longitudinal study has shown that obese adolescents progressing to IGT manifest primary defects in β-cell function, which are aggravated by a progressive decline in insulin sensitivity (67).

17. Insulin resistance is associated with the metabolic syndrome and cardiometabolic risk factors (LOE A)

Regardless of the metabolic syndrome definition used, insulin resistance and high insulin levels are associated with the clustering of cardiometabolic risks associated with metabolic syndrome in a variety of ethnic groups (7, 68, 69).

There are no studies that directly measure in vivo insulin sensitivity and its relationship to atherosclerotic abnormalities in children. Very limited observations suggest a relationship between HOMA and arterial stiffness and fasting insulin levels in youth (70). However, a role for insulin resistance in the early abnormalities of vascular smooth muscles is proposed based on the observation that circulating biomarkers of endothelial dysfunction (intercellular adhesion molecule and E-selectin) are highest, whereas the antiatherogenic adipocytokine adiponectin is lowest among the most insulin-resistant youths (71).

Treatment

18. Diet and weight loss drugs improve insulin sensitivity in adolescents through weight loss and other mechanisms (LOE B)

Dietary fat intake influences insulin sensitivity, with the most consistent effect related to increased fat intake lowering insulin sensitivity rather than reduced fat intake increasing insulin sensitivity (35, 72). However, a consistent effect of fat quality on insulin sensitivity could not be found across 41 adult studies, largely because of design flaws limiting interpretation (73).

A high whole-grain or dietary fiber intake is associated with higher insulin sensitivity and weight loss, and a low intake is associated with lower insulin sensitivity, based upon a questionnaire study in adolescents and prospective crossover studies in adults (74).

Improvement in insulin sensitivity in adolescents on a low glycemic load diet is contradictory to the greater number of studies in adults in which a consistent effect of this diet is not seen on insulin sensitivity (75–77).

Although there are similarities between a low glycemic load and a low-carbohydrate diet, there are no studies evaluating the latter diet’s impact on insulin sensitivity in children. In adolescents receiving either a high-fiber or low glycemic load diet, weight loss was observed with improved insulin sensitivity (74–77). It is unclear whether the improvements in insulin sensitivity were due to weight loss, the diet, or a combination of these factors.

Few studies have examined the impact of a hypocaloric diet on insulin sensitivity in children; however, adult studies have found variable weight loss and improvement in insulin sensitivity.

The weight-reducing drugs sibutramine and orlistat led to an improvement in insulin sensitivity with a reduction in weight of approximately 0.6 SD in children and adolescents (78–80).

19. Exercise and fitness improve insulin sensitivity through weight loss and also mechanisms independent of weight loss in adolescents (LOE A)

Studies specifically exploring the impact of exercise and mechanism of action on insulin resistance are few.

Lifestyle programs including supervised exercise can improve fasting insulin levels as quickly as 2 wk before measurable weight loss (81, 82). Furthermore, lifestyle intervention improved body composition without a change in body weight (83). Available studies suggest that
fitness may play a more important role than body mass index reduction on improvement in insulin sensitivity in obese adolescents (84).

Adequate studies are not available to differentiate the effect of a single session of exercise on insulin sensitivity, as opposed to the training regimen. There appears to be improvement in insulin sensitivity with prescribed aerobic exercise regimens and combinations of aerobic and resistance training (85, 86). However, there is inadequate evidence about the optimal form of exercise. Exercise intensity has not been shown to be correlated with insulin sensitivity. After the cessation of exercise, improved insulin sensitivity levels revert to preexercise levels, and there may even be a rebound phenomenon with greater insulin resistance (82).

20. Multicomponent lifestyle intervention improves insulin sensitivity more than individual lifestyle components in adolescents (LOE B)

There are limited data to show that the effects of nutrition, exercise, and behavioral modification together on insulin sensitivity are more beneficial and sustained than any one component alone (87). Short-term randomized studies of lifestyle and exercise intervention in obese adolescent girls improved insulin sensitivity when compared with no intervention (88).

21. Metformin improves insulin sensitivity in adolescence (LOE B)

Metformin has been shown to improve insulin sensitivity in adolescents with T2D and girls with PCOS, justifying consideration of metformin as a therapeutic tool in these disorders (89, 90). There are conflicting reports on the influence of metformin on insulin sensitivity in insulin-treated, insulin-resistant type 2 diabetics (91).

The safety and efficacy of metformin in the management of T2D in children were confirmed using glycemic control as a proxy for improved insulin sensitivity (92). However, other reports have emphasized that lifestyle and dietary measures can be at least as effective as metformin in these patients (91).

Metformin has been shown to be efficacious in improving insulin sensitivity in obese PCOS girls with IGT (90), but not in obese PCOS girls without IGT (96). In nonobese teenage girls with PCOS, combined flutamide-metformin therapy improved insulin sensitivity (97). Both flutamide and metformin seem to be needed to obtain maximal efficacy on parameters of insulin sensitivity and to ameliorate body composition (98).

However, it has to be stressed that metformin has not been approved for the treatment of children with insulin resistance; therefore, appropriate, well-designed, controlled trials are needed.

Prevention

22. Maternal obesity, gestational diabetes, smoking in pregnancy, and maternal undernutrition should be targeted to lessen obesity and insulin resistance in children (LOE A)

All factors affecting fetal growth are potential candidate targets for prevention purposes.

The most common and important among these risk factors are maternal obesity, gestational diabetes, maternal undernutrition, and smoking during pregnancy (49, 99–102).

23. Breast-feeding should be promoted through public health interventions as a contributing factor to reduce the prevalence of obesity and potential insulin resistance later in life. In addition, ongoing dietary advice starting from weaning has the potential to prevent insulin resistance in the long term (LOE B)

There are no specific data on a direct relationship between breast-feeding and prevention of insulin resistance, but given the association between obesity and reduced insulin sensitivity, breast-feeding should be promoted (103, 104).

Because of the strong link between obesity and insulin resistance, the impact of dietary interventions used to prevent obesity has been examined for its effect on insulin resistance (104). Increased saturated fat intake has been associated with reduced insulin sensitivity in children (35). A healthy low saturated fat and cholesterol diet, started in 7-month-old infants, showed a positive effect on insulin resistance at the age of 9 yr (105).

24. Identification of infants and preschool children at risk for obesity combined with intervention programs to prevent excessive weight gain should be developed and evaluated. Physical activity as a means of increasing insulin sensitivity is an important component of any intervention (LOE B)

Young adults born preterm have lower insulin sensitivity than controls, and weight gain velocity during childhood is associated with lower insulin sensitivity in adulthood (93). Adiposity rebound is a sensitive marker for the risk of developing obesity and its complications, and therefore it should be prevented (55, 94).

Based on available data on the beneficial effect of physical activity on surrogate measures of insulin sensitivity, such as fasting insulin and HOMA for insulin resistance (85, 95), physical activity should be promoted, although further studies using state of the art methodology for insulin sensitivity are required to validate these findings.
Conclusions

This consensus statement highlights the lack of a clear cutoff to define insulin resistance in children and shows that surrogate measures, such as fasting insulin, are poor estimates of insulin sensitivity. Based on current screening criteria and methodology, there is no justification for screening children for insulin resistance, even those who are obese. However, it appears that prevention strategies should be started early in life and, with regard to treatment, lifestyle interventions should be included, whereas metformin should be limited to selected cases. Future research should aim at assessing the following: how to best measure insulin sensitivity; standardization of insulin measurements; identification of strong surrogate biomarkers of insulin resistance; and the potential role of both lifestyle intervention and medications in the prevention and treatment of insulin resistance.

Conference Participants

1. Shin Amemiyia, Department of Pediatrics, Saitama Medical University, Saitama, Japan. 2. Silva Arslanian, Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Gerald Berenson, Tulane Center for Cardiovascular Health, New Orleans, Louisiana. 4. Sonia Caprio, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut. 5. Marie-Aline Charles, INSERM, U780, IFR69, Villejuif and University Paris–Sud, Orsay, France. 6. Francesco Chiarelli, Department of Pediatrics, University of Chieti, Chieti, Italy. 7. Stephen Cook, Department of Pediatrics, Division of General Pediatrics, and Strong Children’s Research Center, University of Rochester School of Medicine and Dentistry, Rochester, New York. 8. Wayne Cutfield, Liggins Institute, University of Auckland, Auckland, New Zealand. 9. Elizabeth Davis, Department of Endocrinology and Diabetes, Princess Margaret Hospital for Children, Perth, Western Australia, Australia. 10. Larry Dolan, Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio. 11. Céline Druet, INSERM, Unité 690, Hôpital Robert Debré, Paris, France. 12. David Dunger, Department of Pediatrics, University of Cambridge, Cambridge, United Kingdom. 13. Anne Fagot-Campagna, Institut de Veille Sanitaire, Département des Maladies Chroniques et Traumatismes, Saint Maurice, France. 14. Carl-Erik Flodmark, Department of Pediatrics, Childhood Obesity Unit, University Hospital, Malmö, Sweden. 15. Earl Ford, Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 16. Jean-François Gautier, Department of Diabetes and Endocrinology, Saint-Louis University Hospital, AP-HP, and INSERM, Paris, France. 17. Elizabeth Goodman, Center for Child and Adolescent Health Policy, MassGeneral Hospital for Children, Harvard Medical School, Boston, Massachusetts. 18. Michael Goran, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 19. Morey Haymond, Department of Pediatrics, Division of Diabetes and Endocrinology, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas. 20. Paul Hoffman, Liggins Institute, University of Auckland, Auckland, New Zealand. 21. Anita Hokken-Koelega, Department of Pediatrics, Division of Endocrinology, Sophia Children’s Hospital, Erasmus Medical Center, Rotterdam, The Netherlands. 22. Lourdes Ibanez, Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, 08950 Esplugues, Barcelona, Spain. 23. Sojung Lee, Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 24. Claire Levy-Marchal, INSERM, Unité 690, Hôpital Robert Debré, Paris, France. 25. Claudio Maffeis, Regional Center for Juvenile Diabetes, University of Verona, Verona, Italy. 26. M. Loredana Marcovecchio, Department of Pediatrics, University of Chieti, Chieti, Italy. 27. Veronica Mericq, Institute of Maternal and Child Research, Faculty of Medicine, University of Chile, Santiago, Chile. 28. Boyd Metzger, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 29. Svante Norgren, Department of Pediatric Medicine, Karolinska University Hospital, Stockholm, Sweden. 30. Ken Ong, Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom. 31. David Pettitt, Sansum Diabetes Research Institute, Santa Barbara, California. 32. Mary Rudolf, University of Leeds and Leeds PCT, Leeds, United Kingdom. 33. Jeffrey Schwimmer, Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, San Diego School of Medicine, San Diego, California. 34. Alan Sinaiko, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 35. Julia Steinberger, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota. 36. Ram Weiss, Department of Human Metabolism and Nutrition, Braun School of Public Health, Hebrew University School of Medicine, Jerusalem, Israel. 37. Chittaranjan Yajnik, Diabetes Unit, KEM Hospital, Pune, India.

Acknowledgments

Address all correspondence and requests for reprints to: Prof. Francesco Chiarelli, M.D., Ph.D., Department of Pediatrics, University of Chieti, Via dei Vestini, 5, Chieti 66013, Italy. E-mail: chiarelli@unich.it.
The conference was partly supported by educational grants from Institut National de la Santé et de la Recherche Médicale (France) and Ipsen (France).

Disclosure Summary: The authors have nothing to declare.

References


58. Ibáñez L, Ong K, Dunger DB, de Zegher F 2006 Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J Clin Endocrinol Metab 91:2153–2158


to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth. Diabetes Care 30:2091–2097


77. Thomas DE, Elliott EJ, Baur L 2007 Low glycemic index or low glycemic load diets for overweight and obesity. Cochrane Database Syst Rev CD005105


